Johnson & Johnson (NYSE:JNJ) subsidiary LifeScan said today it won FDA clearance for wireless integration of its OneTouch Verio Flex blood glucose monitoring system with WellDoc‘s FDA-approved BlueStar diabetes management system.
The OneTouch Verio Flex system is now cleared to automatically wirelessly transmit blood glucose monitoring data to WellDoc’s BlueStar system, which in turn provides patients with real-time feedback and virtual coaching based on patient specifics. The system also keeps the patient’s health care teams informed of their status for better decision making, the company said.
“Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience. Integrating digital solutions such as OneTouch Reveal mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers,” LifeScan world wide prez Valerie Asbury said in a press release.
The companies said they are working with health plans to provide patient access to the integrated system.
The companies inked a deal in March seeking to integrate LifeScan’s OneTouch Verio Flex blood glucose monitoring system and OneTouch Reveal Mobile application with WellDoc’s BlueStar diabetes management platform and mobile app.
The integration of the systems is intended to provide patients with smart monitoring tools and motivational, behavioral and educational coaching that LifeScan claims has been shown to improve patient health.
LifeScan said that in a clinical trial of WellDoc’s platform, patients who used the system showed a 1.9% decrease in glycated hemoglobin level over 12 months, 1.2% higher than the “usual care” group.